SCHEMBL7201040

SCHEMBL7201040

c1ccc(COC2CCCC3OC23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 2/20 0.45
CTSB P07858 2/20 0.45
CTSK P43235 2/20 0.45
CTSV O60911 1/20 0.45
CTSS P25774 1/20 0.45
CTSC P53634 1/20 0.45
CTSF Q9UBX1 1/20 0.45
PSEN1 P49768 3/20 0.43
PSEN2 P49810 3/20 0.43
APH1B Q8WW43 3/20 0.43
NCSTN Q92542 3/20 0.43
APH1A Q96BI3 3/20 0.43
PSENEN Q9NZ42 3/20 0.43
BCHE P06276 2/20 0.39
KCNA5 P22460 1/20 0.39
TACR1 P25103 2/20 0.39
PDE4D Q08499 1/20 0.39
ACHE P22303 1/20 0.38
KLK7 P49862 1/20 0.37
KLK5 Q9Y337 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16194624 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS
SCHEMBL17079965 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS
SCHEMBL16195504 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS
SCHEMBL10303684 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS
SCHEMBL17079964 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS
SCHEMBL17086951 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS
SCHEMBL18384827 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS
SCHEMBL16195226 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS
SCHEMBL20404231 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS
SCHEMBL19985774 1.00 CTSL (0.45) CTSLCTSBCTSKCTSVCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4626423-A1 CDK INHIBITORS AND METHODS AND USE THEREOF Relay Therapeutics, Inc. (US) 2025-10-08 EP disclosed
WO-2024119122-A1 CDK INHIBITORS AND METHODS AND USE THEREOF RELAY THERAPEUTICS, INC. (US) 2024-06-06 WO disclosed
EP-3504176-B1 DIFLUORINATED COMPOUNDS AS DEPIGMENTING OR LIGHTENING AGENTS TFCHEM (FR) 2020-06-17 EP disclosed
US-10640441-B2 Difluorinated compounds as depigmenting or lightening agents TFCHEM (FR) 2020-05-05 US disclosed
US-20190322608-A1 DIFLUORINATED COMPOUNDS AS DEPIGMENTING OR LIGHTENING AGENTS TFCHEM (FR) 2019-10-24 US disclosed
US-9937186-B2 Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2018-04-10 US disclosed
WO-2018037254-A1 DIFLUORINATED COMPOUNDS AS DEPIGMENTING OR LIGHTENING AGENTS TFCHEM (FR) 2018-03-01 WO disclosed
WO-2018037086-A1 DIFLUORINATED COMPOUNDS AS DEPIGMENTING OR LIGHTENING AGENTS TFCHEM (FR) 2018-03-01 WO disclosed
EP-3116860-B1 SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS ICAHN SCHOOL MED MOUNT SINAI (US) 2018-02-07 EP disclosed
WO-2017044572-A1 RING CONSTRAINED DIARYLAMINO SULFONAMIDES AS ANTI-CANCER AGENTS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-03-16 WO disclosed
US-20170015625-A1 SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2017-01-19 US disclosed
EP-3116860-A1 SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS Icahn School of Medicine at Mount Sinai (US) 2017-01-18 EP disclosed
EP-2813491-B1 CYCLOALKANE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2016-11-02 EP disclosed
WO-2015138500-A1 SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2015-09-17 WO disclosed
JP-2003171211-A 2-BENZYLOXY-7-OXABICYCLO[4.1.0]HEPTANE DERIVATIVE AND AGROCHEMICAL, ESPECIALLY HERBICIDE COMPRISING THE SAME KUMIAI CHEM IND CO LTD 2003-06-17 JP disclosed
WO-2001016125-A1 2-BENZYLOXY-7-OXABICYCLO[4.1.0]HEPTANE DERIVATIVES AND HERBICIDE CONTAINING THE SAME KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2001-03-08 WO disclosed
EP-0976707-A1 CYCLOALKYL BENZYL ETHER COMPOUNDS Nissan Chemical Industries, Ltd. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190322608-A1 DIFLUORINATED COMPOUNDS AS DEPIGMENTING OR LIGHTENING AGENTS TYR, MITF, MC1R CTSL 4574/4885CTSB 1495/4885CTSK 1348/4885
US-20170015625-A1 SULFONAMIDES DERIVED FROM TRICYCLYL-2-AMINOCYCLOALKANOLS AS ANTICANCER AGENTS FOXO1, SKP2, FOXK1 CTSL 3073/4885CTSB 3428/4885CTSK 2517/4885
US-10640441-B2 Difluorinated compounds as depigmenting or lightening agents TYR, MITF, MC1R CTSL 4574/4885CTSB 1495/4885CTSK 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.